Crossmark Global Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$428K	Buy	1,293 +12	+0.9%	+$4.08K	0.01%	886
2025 Q4	$509K	Buy	1,281 +57	+5%	+$25.2K	0.01%	830
2025 Q3	$558K	Buy	1,224 +180	+17%	+$73.3K	0.01%	848
2025 Q2	$340K	Buy	1,044 +26	+3%	+$7.19K	0.01%	1043
2025 Q1	$275K	Buy	+1,018	New	+$262K	﹤0.01%	1127
2024 Q4	–	Sell	-914	Closed	-$251K	–	1250
2024 Q3	$251K	Sell	914 -4	-0.4%	-$1.04K	﹤0.01%	1149
2024 Q2	$223K	Buy	+918	New	+$145K	﹤0.01%	1194
2024 Q1	–	Sell	-1,066	Closed	-$204K	–	1326
2023 Q4	$204K	Buy	+1,066	New	+$182K	﹤0.01%	1246
2023 Q3	–	Sell	-1,062	Closed	-$211K	–	1261
2023 Q2	$211K	Sell	1,062 -72	-6%	-$14.3K	﹤0.01%	1233
2023 Q1	$227K	Buy	1,134 +107	+10%	+$22.5K	0.01%	1170
2022 Q4	$244K	Sell	1,027 -67	-6%	-$14.3K	0.01%	1101
2022 Q3	$219K	Buy	+1,094	New	+$209K	0.01%	1135
2018 Q3	–	Sell	-2,059	Closed	-$203K	–	1591
2018 Q2	$203K	Sell	2,059 -310	-13%	-$30.7K	0.01%	1531
2018 Q1	$282K	Sell	2,369 -659	-22%	-$85K	0.01%	1317
2017 Q4	$385K	Buy	3,028 +59	+2%	+$7.41K	0.01%	1191
2017 Q3	$349K	Buy	+2,969	New	+$253K	0.01%	1208
2016 Q3	$349K	Buy	+2,969	New	+$209K	0.01%	1208